MVASI 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung

7680672830025 CH-67283 Konzentrat
MVASI 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung
MVASI 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung
MVASI 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
07/08/2023
Summary of Product Characteristics
Français
07/08/2023
Summary of Product Characteristics
Italien
07/08/2023

Detailed composition

Substance Quantity Type Category
(N/A)
400.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
21.68 MG Substance HBESI

Reimbursement information

Public price
CHF 1063.55
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/07/2020

Authorization holder

Amgen Switzerland AG

6343 Risch

Authorization information

Swissmedic authorization number
67283
Drug name
MVASI, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOPA
ATC Code
L01FG01
Authorization status
Z
Dispensing category
A
First authorization
09/12/2019
Authorization expiration date
31/12/9999
IT Number
07.16.1.
Domain
Human medicine
Field of application
Onkologikum

Package details

Description (FR)
MVASI conc perf 400 mg/16ml flac 16 ml
Description (DE)
MVASI Inf Konz 400 mg/16ml Durchstf 16 ml
Market launch
09/12/2019
Narcotic (BTM)
No

Other package sizes (1)

MVASI conc perf 100 mg/4ml flac 4 ml
1 DUR
GTIN: 7680672830018
View